Physician profile
Raymond Emanuel
NPI 1982799748
$1,407.58
in general payments reported to CMS, 2019-2025
9 companies · $74.66 in 2025
The $74.66 reported for 2025 was less than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $228 · 2023: $392 · 2024: $713 · 2025: $74.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,179.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $556.60 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $267.97 | 2023-2025 | Uzedy, Austedo Xr |
| Indivior INC. | $162.75 | 2023-2024 | Perseris |
| Abbvie INC. | $151.71 | 2022-2024 | |
| Neurocrine Biosciences, INC. | $71.69 | 2022-2023 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $63.17 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $52.91 | 2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $51.96 | 2024 | Invega Sustenna, Invega Trinza |
| Janssen Scientific Affairs, LLC | $28.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Emanuel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.